Kornimate/medical-research-clean huggingface dataset:
app based dexterity training in multiple sclerosis

Conditions: Multiple Sclerosis

Summary: multiple sclerosis (ms) is a chronic inflammatory disease of the central nervous system and the most common cause of non-traumatic disability in young adults (kamm et al. 2014; vanbellingen \& kamm, 2016). it is a heterogeneous disease, which is associated with long-term disability, leading to reduced quality of life (qol). disease-modifying pharmacological therapies (dmt) decrease activity and progression of the disease, and symptomatic pharmacological treatments reduce complaints to a certain extent, however ms patients often still suffer from various neurological deficits during the course of their disease (kamm et al. 2014). consequently, specific non-pharmacological therapies are needed in order to further reduce disability, eventually resulting in better qol (lamers et al. 2016; vanbellingen \& kamm, 2016). impaired dexterity is a frequently observed impairment, affecting up to 76% of patients with ms (johannson et al. 2007). the different neurological deficits caused by ms, such as ataxia, spasticity, sensory-motor deficits, and apraxia may be alone or in combination, impair manual dexterity (kamm et al. 2012; heldner, vanbellingen et al. 2014). ms patients experience impairments in the performance of several activities of daily living (adl), such as grooming, cooking, etc. sometimes these problems are even associated with loss of work, and lack of social integration (chruzander et al. 2013). the effectiveness of the app based exercises still needs to be proven. with respect to dexterity, a first new app has been developed called "finger zirkus", by a team of experts including an occupational therapist, graphic designer, and it expert. the app is already available to be downloaded from google play store or apple store (see for more details: www.fingers-in-motion.de).


Eligibility criteria:
inclusion criteria: * the inclusion criteria for ms patients are as follows: males and females, age 18 to 75, diagnosis of ms (primary or secondary progressive, relapsing-remitting) following the mcdonald criteria (polman et al. 2011). in addition, patients must report difficulties in manual dexterity that impact adl and/or have a pathological nine hole peg test (9hpt) or coin rotation test (crt) according to cut-off values (mathiowetz et al. 1985; heldner, vanbellingen et al. 2014). exclusion criteria: * the exclusion criteria will be other conditions that may hand function or, impaired cognitive functioning (mini mental status examination score less than 24).
investigation of the glaukos® trabecular micro-bypass system, model is3, in subjects with refractory glaucoma

Conditions: Glaucoma

Summary: prospective, multi-center, single-arm clinical trial to evaluate the safety and effectiveness of the glaukos® trabecular micro-bypass system model is3 (three stents per study eye) in subjects with refractory glaucoma.

this is a prospective, multi-center, single arm, open-label clinical trial of the is3 system. up to 65 qualified subjects will be implanted with three g2-w stents in one eye and will be followed for 12 months postoperatively.

Eligibility criteria:
inclusion criteria: * diagnosis of refractory open-angle glaucoma (including pigmentary and pseudoexfoliative glaucoma) that is uncontrolled despite medical therapy and/or prior conventional incisional intraocular glaucoma surgeries. * phakic or pseudophakic. * males or females, 45 years of age or older. exclusion criteria: * traumatic, uveitic, neovascular, or angle-closure; or glaucoma associated with vascular disorders. * active corneal inflammation or edema. * retinal disorders not associated with glaucoma.

Keywords: refractory
electronic prescribing and electronic transmission of discharge medication lists

Conditions: Medication Errors

Summary: the purpose of this study is twofold: 1. to measure the effects of transitioning from one electronic prescribing system to another in the ambulatory setting on medication errors and human-computer interactions 2. to evaluate the impact of electronic transmission of discharge medication lists to the ambulatory setting on medication discrepancies and adverse drug events


Eligibility criteria:
inclusion criteria: * physicians or nurse practitioners with at least 4 clinic sessions per week

Keywords: medication errors adverse drug events patient safety electronic prescribing systems medication reconciliation
b cell responses in covid-19

Conditions: COVID 19

Summary: in this study, we will develop techniques to optimize the in vitro production of human monoclonal antibodies.


Eligibility criteria:
inclusion criteria: * age \>18 at time of signing informed consent form * signed informed consent form exclusion criteria: * ongoing drug abuse * active or history of neoplastic malignancy * active autoimmune disease ongoing treatment with immunosuppressive therapy * ischemic heart disease * evidence of positive hiv, hcv, hbv test * diabetes * failure to sign informed consent form
placement of nasogastric tubes for gastric decompression in patients with bronchiolitis

Conditions: Bronchiolitis

Summary: this study aims to evaluate whether placing nasogastric tubes for gastric decompression improves respiratory distress for patients with bronchiolitis who are receiving oxygen via high-flow nasal cannula.

all patients will be consented per irb procedure. the study will be a prospective study. study participants will be enrolled after placement on high flow nasal cannula. the respiratory therapist or study staff will use a bronchiolitis scoring tool, the marlais risk of admission score, to assess the respiratory status of patients after placement on high flow nasal cannula, and prior to placement of ng tube to establish a baseline measurement. this tool includes the following components: respiratory rate, oxygen saturation, heart rate, age, and length of illness. an ng tube will then be placed. thirty minutes and sixty minutes after placement of the ng tube, the respiratory therapist or study team will again use this scoring tool to assess the respiratory status of the patient. after 60 minutes the study will be concluded. as subject will be requiring oxygen use, admission to an inpatient unit is required. the ng tube will be removed at the discretion of the provider or the admitting physician, who may choose to keep it in at their discretion.

Eligibility criteria:
inclusion criteria: * diagnosis of bronchiolitis by the attending physician * on high flow nasal cannula (4 liters or greater) * ages 0 months to 23 months exclusion criteria: * diagnosis of bacterial pneumonia * history of cranio-facial anomalies * history of congenital heart disease * history of g-tube dependence * history of short gut syndrome * history of tracheostomy or current tracheostomy
effect of tai chi on symptoms in hemodialysis patients

Conditions: Dialysis; Complications; Chinese Medicine; Quality of Life

Summary: the goal of this clinical trial is to learn about the effect of tai chi on symptoms in hemodialysis patients.the main question\[s\] it aims to answer are: the effect of tai chi on symptoms or the quality of life in hemodialysis patients .participants will be divided into three groups, one group will be asked to do tai chi for 30 minutes three times a week, and the other group will be asked to do tai chi imagery for 30 minutes three times a week. the comparison group will be given usual care. researchers will compare the efficacy of symptoms and quality of life in dialysis patients in each group.


Eligibility criteria:
inclusion criteria: * age≥ 18; * dialysis age≥ 3 months; * survival≥ 12 months; * the patient has the ability to move independently, can learn independently, and has no reading and comprehension disabilities; * informed consent exclusion criteria: * inability to move autonomously; * have a mental disorder; * other serious complications occur
door to unloading with impella cp system in acute myocardial infarction - safety and feasibility study

Conditions: STEMI

Summary: direct active unloading of the left ventricle with the impella cp system prior to ppci in patients with st-elevation myocardial infarction (stemi) is safe and feasible

a multi-center, prospective, randomized, two-arm feasibility trial to assess the potential role of unloading with the impella cp prior to revascularization in reducing infarct size. the study design includes 1:1 randomization between: 1) delay arm: 30 minutes of unloading with impella cp prior to primary percutaneous coronary intervention (ppci); and 2) immediate arm: initiation of impella cp unloading followed immediately by ppci. study hypothesis: direct active unloading of the left ventricle with the impella cp system prior to ppci in patients with st-elevation myocardial infarction (stemi) is safe and feasible

Eligibility criteria:
main inclusion criteria: * age 21-80 years * first myocardial infarction * acute anterior stemi with ≥ 2 mm in 2 or more contiguous anterior leads or≥ 4 mm total st-segment deviation sum in the anterior leads * signed informed consent main exclusion criteria: * cardiogenic shock defined as: systemic hypotension (systolic bp less than 90 mmhg or the need for inotropes/pressors to maintain a systolic bp greater than 90mmhg) plus one of the following: any requirement for pressors/inotropes prior to arrival at the cath lab, clinical evidence of end organ hypoperfusion, lactate level greater than 2.5mmol/l * inferior stemi or suspected right ventricular failure * suspected or known pregnancy * suspected active infection * history or known hepatic insufficiency prior to catheterization * on dialysis therapy * known contraindication to: * undergoing mri or use of gadolinium * heparin, pork, pork products or contrast media * receiving a drug-eluting stent * participation in the active treatment or follow-up phase of another clinical study of an investigational drug or device

Keywords: infarct size impella unloading left ventricle ppci stemi
predictive value of albumin - bilirubin score and crp - albumin - lymphocyte index for hcc prognosis after radical resection

Conditions: Hepatocellular Carcinoma (HCC); Hepatocellular Carcinoma (HCC) Prognosis

Summary: evaluate the predictive value of the cally index and albi grading for the prognosis of patients with hepatocellular carcinoma (hcc) after radical resection, so as to provide a reference for clinical treatment.

china bears a heavy burden of liver cancer. in 2022, there were 370,000 new cases and 320,000 deaths, ranking 4th in incidence and 2nd in mortality among malignant tumors. hcc, accounting for over 80% of primary liver cancer, also has high incidence and fatality rates. radical resection, the main cure method, has a 5-year recurrence rate over 60%, so identifying recurrence risk factors is crucial. previously, the child - pugh score was used for liver function evaluation, but its assessment of ascites and hepatic encephalopathy was subjective. quantitative systems like meld also had limitations. over 80% of hcc develops from cirrhosis, and inflammatory and immunonutritional indices are important in cancer development. nlr, plr, etc., show inconsistent predictive power, and the cally index, though better, needs improvement. bilirubin is a key predictor, and albi grading can precisely quantify liver function, related to hcc recurrence and survival. this study combines albi and cally to create a four - dimensional system, expected to reflect hcc recurrence risk. as this combined prediction research is scarce, this study evaluates their predictive value for hcc patients after radical resection, guiding clinical treatment.

Eligibility criteria:
inclusion criteria: * (1) age ≥ 18 years old (2) postoperative pathological examination confirmed hepatocellular carcinoma (hcc) (3) no other anti-tumor treatment was received before surgery (4) radical resection was performed, and the pathological examination under the microscope showed negative surgical margins. exclusion criteria: * (1) complicated with other malignant tumors. (2) incomplete clinicopathological data and prognostic information. (3) received preoperative anti-cancer treatment. (4) follow-up less than 1 month after hepatectomy. (5) patients with surgical contraindications before surgery, such as portal vein tumor thrombus and distant metastasis.

Keywords: hcc hepatocellular carcinoma albumin-bilirubin score cally albi hepatocellular carcinoma (hcc) prognosis
breathe 5-ol: tracleer (bosentan) in patients with pulmonary arterial hypertension related to eisenmenger physiology

Conditions: Pulmonary Arterial Hypertension

Summary: this 6-month open label study will evaluate the long term safety of bosentan (via oxygen saturation) and efficacy (exercise capacity) in patients who have completed the breathe-5 study (pah related to eisenmenger physiology). treatment duration is 6 months.

this is a multicenter, open-label, single -arm study with bosentan, initial dose of 62.5 mg b.i.d., with a target dose of 125 mg b.i.d. all patients will be assessed for eligibility during the baseline visit (same as week 16, end of study breathe-5 visit), and will have the option to enter into the open-label extension study at a starting dose of 62.5 mg b.i.d., for safety reasons. visit 2 is required as a safety visit to assess oxygen saturation (spo2) after 1 week of bosentan treatment. patients will return for visit 4 after 4 weeks of treatment, and the dose will be up-titrated to 125 mg b.i.d. or maintained at 62.5 mg b.i.d. at the judgement of the investigator. data will be collected for a total of 24 weeks or until the sponsor decides to stop the study. if the results from study ac-052-403 or ac-052-405 demonstrate significant safety issues, this extension study may be terminated at the sponsor's request.

Eligibility criteria:
inclusion criteria: 1. patients stable with pah upon completion of the breathe-5 randomized, double-blind, placebo- controlled 16-week study. 2. for female patients, only non-pregnant women who are surgically sterile, postmenopausal or have documented infertility (over 50 years of age and amenorrheic for at least 1 year), or those of childbearing potential using one of the following methods of contraception: barrier-type devices (e.g., condom, diaphragm) used only in combination with a spermicide. a double-barrier method is recommended; intrauterine devices (iuds); oral or implanted contraceptives, if used in combination with a barrier method. 3. patients providing written informed consent. exclusion criteria: 1. patients who withdrew prematurely from breathe-5, ac-052-405. 2. patients who are pregnant or nursing. 3. patients who are receiving epoprostenol or prostacyclin analogues, or are expected to receive any of these drugs during the study. 4. patients with ast and/or alt values greater than 3 times the upper limit of normal. 5. patients with hemoglobin or hematocrit that is more than 30% below the normal range (patients with secondary polycythemia are permitted in the study). 6. patients with systolic blood pressure \< 85 mm hg. 7. patients taking phosphodiesterase inhibitors, other endothelin receptor antagonists or are receiving another investigational product. 8. patients active on organ transplant list. 9. patients who are receiving or expected to receive glyburide, cyclosporin a or tacrolimus. 10. patients not able to comply with the protocol or adhere to therapy.

Keywords: bosentan pah related to eisenmenger physiology tracleer
comparison of 2 laryngoscopes for endotracheal intubation in children younger than 2 years old

Conditions: Endotracheal Intubation

Summary: this is a prospective randomized clinical study to be performed in pediatric patients under the age of 2 years who are undergoing surgical procedures requiring endotracheal intubation. time to endotracheal intubation will be compared between patients intubated using a glidescope® video laryngoscope, those intubated with a storz dci® video laryngoscope, and those intubated by standard direct laryngoscopy. the study hypothesis is that the time to endotracheal intubation will be decreased in the storz dci® video laryngoscope group when compared to the glidescope® video laryngoscope group and standard laryngoscopy.


Eligibility criteria:
inclusion criteria: * pediatric patients under the age of 2 years undergoing surgeries requiring endotracheal intubation at llumc will be eligible for participation in this study exclusion criteria: * children with increased pulmonary aspiration risk; * prior documentation of difficult endotracheal intubation; * those that lack legal representative consent

Keywords: breathing tube placement
human immunodeficiency virus (hiv) postexposure prophylaxis (pep) with darunavir/ritonavir (drv/r)

Conditions: Human Immunodeficiency Virus (HIV)

Summary: the primary purpose of this study is to assess the rate of early discontinuation from randomized human immunodeficiency virus (hiv) postexposure prophylaxis (pep) for any reason other than confirmation of the negative hiv infection status of the index person in patients receiving hiv pep for at least 28 and a maximum of 30 days.

this is a randomized (study medication assigned by chance), open-label (all people involved know the identity of the intervention), active-controlled (patients are assigned to either a recognized effective treatment or the study medication), parallel-group (each treatment group will be treated at the same time), multicenter study comparing drv/r pep (drv/r administered with 2 nrtis selected at the discretion of the investigator) to standard of care pep (as per german-austrian guidelines) in patients at risk of hiv infection due to hiv exposure through occupational injury and non-occupational exposure. this study consists of screening period, treatment period and a follow up period. hiv pep will be administered for a total of at least 28 days and maximum of 30 days during treatment period, including any prestudy hiv pep initiated before screening. approximately 318 patients will be screened and enrolled to ensure that at least 131 patients are randomly assigned to receive drv/r pep or standard of care pep. safety will be evaluated during the entire study period. data relating to a patient's functional impairment in conjunction with hiv pep will be collected on day 1 as baseline data, and further on days 14 and 28 as well as at month 3.

Eligibility criteria:
inclusion criteria: * occupational injury and non-occupational exposure with documented human immunodeficiency virus (hiv) exposure, or potential for hiv exposure * indication for hiv postexposure prophylaxis (pep), as determined by the treating physician and/or the investigator * women must be: postmenopausal (for at least 2 years), surgically sterile, using oral contraceptives * willing to continue hiv pep for 28 days exclusion criteria: * positive hiv rapid test * history of liver or renal insufficiency; significant cardiac, vascular, pulmonary, gastro intestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances * pregnant or breast-feeding * any condition that, in the opinion of the investigator, would compromise the well-being of the participant or the study or prevent the participant from meeting or performing study requirements

Keywords: human immunodeficiency virus (hiv) post exposure prophylaxis drv/r occupational injury non-occupational exposure prezista darunavir/r
effectiveness of transcranial magnetic stimulation treatment in patients diagnosed with postpolio syndrome: a randomized controlled double-blind study

Conditions: Postpolio Syndrome

Summary: the study is planned to include a minimum of 26 patients with paralytic poliomyelitis who meet the pps diagnostic criteria (1). patients will be randomized into two groups, and one group will receive only the exercise therapy used in standard treatment, while the other group will receive transcranial magnetic stimulation (tms) therapy in addition to exercise. tms will be applied to the study group 5 times a week for 2 weeks, for a total of 10 sessions. the protocol to be applied during the study will be set to 1 hz, and each session will last 15 minutes. all participants will be evaluated with muscle strength (manual muscle testing), 6-minute walking test, polio-related problems inventory, vas pain, vas fatigue, fatigue severity scale, beck depression inventory, nottingham health profile scales before, at the end of treatment, and at the end of the 3rd month. as a result of the evaluation, the potential positive effects of tms on patients with pps will be measured and evidence-based data for the use of this treatment modality in patients with pps will be obtained. this study will be the first to evaluate the effectiveness of tms in a controlled manner in a patient group with pps. as a result of the evaluation, the potential positive effects of tms on patients with pps will be measured and evidence-based data will be obtained for the use of this treatment modality in patients with pps.


Eligibility criteria:
inclusion criteria:-having been diagnosed with pps (postpolio syndrome) -having not received tms treatment before - exclusion criteria:-history of epilepsy * presence of another disease that may be associated with the symptoms * inability to ambulate independently * presence of a neurological, psychiatric or vision-related problem that may prevent the patient from answering the questionnaires * presence of ferromagnetic material implanted in the body * organic brain pathology (vascular, traumatic, tumoral, etc.) * history of use of drugs that lower the seizure threshold (if not receiving antiepileptic treatment) * severe or recent heart disease * alcoholism * pregnancy

Keywords: postpolio poliomyelit tms rtms gait speed